ArticleCureus2025
Aggressive Primary Cutaneous Apocrine Carcinoma of the Scalp: A Clinical Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PD-1 blockade combined with anlotinib and bicalutamide for metastatic primary cutaneous apocrine carcinoma: a case report and literature review.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary cutaneous apocrine carcinoma (PCAC) is a rare malignancy originating from the apocrine glands of the skin. It is predominantly found in regions rich in apocrine glands, such as the axilla and anogenital area. Scalp involvement is rare, and the disease's aggressive behavior further complicates its management. A 78-year-old male with a history of primary cutaneous apocrine carcinoma (PCAC) of the neck, previously managed with craniotomy, radiation, and chemotherapy, presented five years later with recurrence and bone metastasis. Six years after the initial diagnosis, he developed enlarging masses in the neck, necessitating extensive surgical resection. Histopathology confirmed primary cutaneous cribriform apocrine carcinoma with positive markers for CK7, GCDFP-15, EMA, and androgen receptors. Further molecular analysis performed on a fine-needle aspiration biopsy revealed pathogenic and likely pathogenic alterations, including HRAS G13R and FBXW7 Y545C. The patient underwent successful resection of the neck apocrine carcinoma by neurosurgeons, followed by soft tissue reconstruction by plastic surgeons. This case highlights the importance and challenges of diagnosing and managing a scalp PCAC with recurrence and bone metastasis and the need for more aggressive follow-up and treatment strategies in similar cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.